Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab... Objectives To investigate early changes in tumour perfusion parameters by dynamic contrast-enhanced ultrasonography (D- CEUS) and to identify any correlation with survival and tumour response in patients with metastatic colorectal cancer (CRC) treated with bevacizumab (B). Methods Thirty-seven patients randomized to either chemotherapy (C) plus B or C alone were considered for this study. D- CEUS was performed at baseline and after the first treatment cycle (day 15). Four D-CEUS perfusion parameters were consid- ered: derived peak intensity (DPI), area under the curve (AUC), slope of wash-in (A) and time to peak intensity (TPI). Results In patients treated with C plus B, a ≥22.5%reductioninDPI, ≥20 % increase in TPI and ≥10 % reduction in AUC were correlated with higher progression-free survival in the C+B arm (p = 0.048, 0.024 and 0.010, respectively) but not in the C arm. None of the evaluated parameter modifications had a correlation with tumour response or overall survival. Conclusions D-CEUS could be useful for detecting and quantifying dynamic changes in tumour vascularity as early as 15 days after the start of B-based therapy. Although these changes may be predictive of progression-free survival, no correlation with response or overall survival was found. Key Points � http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Radiology Springer Journals

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer

Loading next page...
 
/lp/springer_journal/dynamic-contrast-enhanced-ultrasonography-d-ceus-for-the-early-Us8K0lEJLL
Publisher
Springer Journals
Copyright
Copyright © 2018 by European Society of Radiology
Subject
Medicine & Public Health; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound; Internal Medicine
ISSN
0938-7994
eISSN
1432-1084
DOI
10.1007/s00330-017-5254-5
pmid
29417252
Publisher site
See Article on Publisher Site

Abstract

Objectives To investigate early changes in tumour perfusion parameters by dynamic contrast-enhanced ultrasonography (D- CEUS) and to identify any correlation with survival and tumour response in patients with metastatic colorectal cancer (CRC) treated with bevacizumab (B). Methods Thirty-seven patients randomized to either chemotherapy (C) plus B or C alone were considered for this study. D- CEUS was performed at baseline and after the first treatment cycle (day 15). Four D-CEUS perfusion parameters were consid- ered: derived peak intensity (DPI), area under the curve (AUC), slope of wash-in (A) and time to peak intensity (TPI). Results In patients treated with C plus B, a ≥22.5%reductioninDPI, ≥20 % increase in TPI and ≥10 % reduction in AUC were correlated with higher progression-free survival in the C+B arm (p = 0.048, 0.024 and 0.010, respectively) but not in the C arm. None of the evaluated parameter modifications had a correlation with tumour response or overall survival. Conclusions D-CEUS could be useful for detecting and quantifying dynamic changes in tumour vascularity as early as 15 days after the start of B-based therapy. Although these changes may be predictive of progression-free survival, no correlation with response or overall survival was found. Key Points �

Journal

European RadiologySpringer Journals

Published: Feb 7, 2018

References